Evidence map›Paper›PMID 39684383›Full record

ReviewInternational journal of molecular sciences2024

Vesicles: New Advances in the Treatment of Neurodegenerative Diseases.

Domenico Nuzzo, Antonella Girgenti, Laura Palumbo, Flores Naselli, Martina Bavetta, Giovanni Marfia, Pasquale Picone

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Domenico NuzzoInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.ORCID 0000-0002-4325-417X
Antonella GirgentiInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.
Laura PalumboInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.
Flores NaselliInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.
Martina BavettaInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.
Giovanni MarfiaLaboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-5849-7000
Pasquale PiconeInstitute for Biomedical Research and Innovation, CNR, Via U. La Malfa 153, 90146 Palermo, Italy.ORCID 0009-0008-2828-1912

Funding

European Union (NextGeneration EU), through the MUR-PNRR project SAMOTHRACE ECS00000022; CUPB63C22000620005
6 · The paper itself

Abstract

Neurodegenerative diseases are characterized by brain lesions that limit normal daily activities and represent a major challenge to healthcare systems worldwide, with a significant economic impact. Nanotechnology is the science of manipulating matter at the nanoscale, where materials exhibit unique properties that are significantly different from their larger counterparts. These properties can be exploited for a wide range of applications, including medicine. Among the emerging therapeutic approaches for the treatment of neurodegenerative diseases, nanotechnologies are gaining prominence as a promising avenue to explore. Here, we review the state of the art of biological and artificial vesicles and their biological properties in the context of neurodegenerative diseases. Indeed, nanometric structures such as extracellular vesicles and artificial vesicles represent a promising tool for the treatment of such disorders due to their size, biocompatibility, and ability to transport drugs, proteins, and genetic material across the blood-brain barrier to target specific cells and brain areas. In the future, a deeper and broader synergy between materials science, bioengineering, biology, medicine, and the discovery of new, increasingly powerful delivery systems will certainly enable a more applied use of nanotechnology in the treatment of brain disorders.

Indexed as

Blood-Brain BarrierExtracellular VesiclesNeurodegenerative DiseasesAnimalsHumansNanoparticle Drug Delivery SystemNanotechnologyNanoparticle Drug Delivery Systemartificial vesiclesextracellular vesiclesnanotechnologiesneurodegenerative diseases

Identifiers

PMID39684383
PMCPMC11641380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.